Literature DB >> 17544820

C1q binding and complement activation by prions and amyloids.

Robert B Sim1, Uday Kishore, Christian L Villiers, Patrice N Marche, Daniel A Mitchell.   

Abstract

C1q binds to many non-self and altered-self-materials. These include microorganisms, immune complexes, apoptotic and necrotic cells and their breakdown products, and amyloids. C1q binding to amyloid fibrils found as extracellular deposits in tissues, and subsequent complement activation are involved in the pathology of several amyloid diseases, such as Alzheimer's disease. Prion diseases, such as scrapie also involve formation of amyloid by polymerization of the host prion protein (PrP). Complement activation is likely to contribute to neuronal damage in the end stages of prion diseases, but is also thought to participate in the initial infection, dissemination and replication stages. Infectious prion particles are likely to bind C1q and activate the complement system. Bound complement proteins may then influence the uptake and transport of prion particles by dendritic cells (DCs) and their subsequent proliferation at sites such as follicular DCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544820     DOI: 10.1016/j.imbio.2007.04.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  19 in total

1.  Complement protein C1q forms a complex with cytotoxic prion protein oligomers.

Authors:  Paul Erlich; Chantal Dumestre-Pérard; Wai Li Ling; Catherine Lemaire-Vieille; Guy Schoehn; Gérard J Arlaud; Nicole M Thielens; Jean Gagnon; Jean-Yves Cesbron
Journal:  J Biol Chem       Date:  2010-04-21       Impact factor: 5.157

2.  Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation.

Authors:  Ming Li; Rahasson R Ager; Deborah A Fraser; Natalia O Tjokro; Andrea J Tenner
Journal:  Mol Immunol       Date:  2008-04-08       Impact factor: 4.407

Review 3.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

Review 4.  Inflammation in neurodegenerative diseases.

Authors:  Sandra Amor; Fabiola Puentes; David Baker; Paul van der Valk
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

5.  Complement activation by phospholipids: the interplay of factor H and C1q.

Authors:  Lee Aun Tan; Bingbin Yu; Francis C J Sim; Uday Kishore; Robert B Sim
Journal:  Protein Cell       Date:  2010-12-10       Impact factor: 14.870

6.  Reaction of complement factors varies with prion strains in vitro and in vivo.

Authors:  Rie Hasebe; Gregory J Raymond; Motohiro Horiuchi; Byron Caughey
Journal:  Virology       Date:  2012-01-03       Impact factor: 3.616

Review 7.  Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.

Authors:  Wendy Noble; Claire J Garwood; Diane P Hanger
Journal:  Prion       Date:  2009-04-21       Impact factor: 3.931

8.  Genetic depletion of complement receptors CD21/35 prevents terminal prion disease in a mouse model of chronic wasting disease.

Authors:  Brady Michel; Adam Ferguson; Theodore Johnson; Heather Bender; Crystal Meyerett-Reid; Bruce Pulford; Adriana von Teichman; Davis Seelig; John H Weis; Glenn C Telling; Adriano Aguzzi; Mark D Zabel
Journal:  J Immunol       Date:  2012-09-21       Impact factor: 5.422

Review 9.  Fundamental role of C1q in autoimmunity and inflammation.

Authors:  Myoungsun Son; Betty Diamond; Frances Santiago-Schwarz
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

10.  Apolipoproteins inhibit the innate immunity activated by necrotic cells or bacterial endotoxin.

Authors:  Nam-Hyuk Cho; Seung-Yong Seong
Journal:  Immunology       Date:  2008-12-17       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.